Chronic Obstructive Pulmonary Disease Drug Pipeline Market Report 2022: Comprehensive Insights About 70+ Companies and 70+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic Obstructive Pulmonary Disease – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines. The assessment part of the report embraces, in depth Chronic Obstructive Pulmonary Disease commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Obstructive Pulmonary Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters

This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Obstructive Pulmonary Disease Emerging Drugs

Benralizumab: AstraZeneca

Benralizumab (FASENRA) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophil and attracts natural killer cells to induce rapid and near-complete depletion of eosinophil via apoptosis (programmed cell death). The drug is approved by the US FDA for asthma and is currently being developed for other respiratory and immunological disorders such as COPD, atopic dermatitis, and others.

The drug was earlier in GALATHEA and TERRANOVA trials (randomized, double-blinded, placebo-controlled, parallel-group trials that assessed the safety and efficacy of Fasenra 30mg and 100mg for preventing COPD exacerbations). At present, the drug is in RESOLUTE (Phase III trial) to evaluate its efficacy and safety.

MV130: Inmunotek S.L.

MV130 (BACTEK) is a bacterial mucosal vaccine or a bacterial polyvalent vaccine in a spray that is administered sublingually to treat recurrent respiratory tract infections in children and adults. MV130 plays a relevant role in modulating the functional activity of the innate and adaptive immune response by stimulating dendritic cells, which are part of innate immunity. A Phase III clinical trial is evaluating MV130 in patients with COPD. At present, the trial is ongoing in Spain.

SB-240563: GlaxoSmithKline

SB-240563 (mepolizumab) is a humanized monoclonal antibody that blocks human interleukin 5 (hIL-5) from binding to its receptor. Initial clinical studies investigated the safety and efficacy of SB-240563 for the treatment of asthma and atopic dermatitis (AD). SB-240563 reduced peripheral and tissue eosinophils in patients with asthma and healthy volunteers. Currently, it is in the Phase III stage of the clinical trials.

SAR440340: Sanofi/Regeneron

SAR440340 (Itepekimab) is a humanized IgG4P monoclonal antibody that blocks human interleukin 33 (hIL-33) from binding to its receptor. IL-33 is an epithelial cytokine that initiates and amplifies innate and adaptive type 2 and 1 inflammatory pathways in response to epithelial insults due to exposure to allergens, viruses, cigarette smoke, and pollutants. SAR440340 was invented using Regeneron’s proprietary VelocImmune technology that yields optimized fully-human antibodies and is being developed jointly by Regeneron and Sanofi as part of a global collaboration agreement.

CHF 6001: Chiesi Farmaceutici S.p.A.

CHF6001 is a novel inhaled phosphodiesterase-4 (PDE-4) inhibitor developed as an extrafine formulation (i.e., with mass median aerodynamic diameter? ??2??m) and low systemic exposure. This allows CHF6001 to reach a therapeutic concentration in the target organ, the lung, with reduced systemic exposure, limiting systemic adverse effects. The drug is administered through a dry powder inhaler (DPI NEXThaler).

YPL 001: Yungjin Pharm. Co., Ltd.

YPL 001 is a drug molecule that belongs to the anti-inflammatory and anti-histamine class of drugs. The drug is being developed for COPD. YPL-001 is a product developed using wild chives, which grow naturally in nature, as a raw material. A Phase II trial was conducted in US hospitals to assess the drug’s safety in patients with moderate-to-severe COPD. In Phase I studies, YPL-001 was well tolerated in healthy subjects following single (up to 320 mg) and multiple (up to 240 mg twice daily [BID]) oral doses with no serious adverse events (AEs).

Key Topics Covered:

Introduction

Executive Summary

Chronic Obstructive Pulmonary Disease: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
• Chronic Obstructive Pulmonary Disease – The Publisher’s Analytical Perspective

In-depth Commercial Assessment

• Chronic Obstructive Pulmonary Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Chronic Obstructive Pulmonary Disease Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Benralizumab: AstraZeneca

• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report

Mid Stage Products (Phase II)

• Comparative Analysis

YPL 001: Yungjin Pharm. Co., Ltd.

• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report

Early stage products (Phase I/II)

• Comparative Analysis

CHF6366: Chiesi Farmaceutici

• Product Description
• Research and Development
• Product Development Activities
• Drug profiles in the detailed report

Inactive Products

• Comparative Analysis
• Chronic Obstructive Pulmonary Disease Key Companies
• Chronic Obstructive Pulmonary Disease Key Products
• Chronic Obstructive Pulmonary Disease- Unmet Needs
• Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
• Chronic Obstructive Pulmonary Disease- Future Perspectives and Conclusion
• Chronic Obstructive Pulmonary Disease Analyst Views
• Chronic Obstructive Pulmonary Disease Key Companies

Appendix

Companies Mentioned

• GlaxoSmithKline
• Sanofi
• Chiesi Farmaceutici S.p.A.
• United Therapeutics Corporation
• Verona Pharma plc
• AstraZeneca
• Immunotek
• Astrazeneca
• Yungjin Pharm. Co., Ltd.
• Pulmotect, Inc.
• Tetherex Pharmaceutical
• CSL Behring; Grifols Biologicals
• AstraZeneca
• Novartis
• Genentech
• Vertex Pharmaceuticals
• Glenmark Pharmaceuticals
• EmeraMed
• Afimmune
• Mereo BioPharma
• Synairgen
• Adamis Pharmaceuticals
• Quercegen Pharmaceuticals LLC
• Regend Therapeutics
• Idorsia Pharmaceuticals
• Meridigen Biotech Co., Ltd.
• Pulmatrix
• Eisai
• GlaxoSmithKline
• Boehringer Ingelheim
• EpiEndo Pharmaceuticals
• 3SBio
• OmniSpirant
• Rhizen Pharmaceuticals
• Foresee Pharmaceuticals
• Brickell Biotech

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/uayxey

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900